Mannose.
Research-backed compound with potential health benefits.
Reviewed March 2026
- Category
- Compound
What Mannose is, and what it does.
- Does it work
- Good evidence for UTI-prone individuals. Works for prevention, not treatment.
- How much to take
- Start with 500mg to 2,000mg a day, which is the daily maintenance band. Trials have used 4,000mg, a research condition rather than a daily target. Splitting it across the day suits many people.
- Time to feel it
- Absorbed within an hour or two, and urinary mannose rises the same day. Changes in urinary comfort are read across days of steady use rather than one dose.
- The first dose
- It's absorbed within an hour or two and urinary mannose rises the same day. There's no sensation attached to that. The change sits in what's in your urine, not in how you feel.
- With regular use
- Across weeks of daily use, urinary comfort is what the human work has tracked. Nothing builds up in tissue, since most of an absorbed dose leaves in urine largely unchanged.
- How well tolerated
- Generally considered well tolerated at normal doses.
- How it feels
- It's a mildly sweet powder that dissolves in water. No lift, no sedation. The change shows up in urinary comfort across days of steady use rather than as a sensation.
- The overlooked benefit
- Past the urinary angle, mannose is the donor sugar for N-linked glycosylation and for the mannose-6-phosphate tag that routes enzymes into the lysosome.
500 to 2,000mg a day is where Mannose works.
Source: Kranjcec et al., World J Urol 2014; D-mannose UTI prevention studies
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Mannose is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- urinary tract comfortRandomised trial
- blocking bacterial FimH adhesion to urinary surfacesIn vitro study
- supply of the donor sugar for N-linked glycosylationNarrative review
- urinary excretion of an oral dose largely unchangedRandomised trial
Questions people ask about Mannose.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Mannose occupies the FimH lectin on type 1 fimbriae so bacteria attach to the sugar rather than to the bladder lining, while cranberry proanthocyanidins interfere with P-type fimbrial attachment. The two cover different adhesins, which is why they are formulated together.
Mannose, glucose and galactose share intestinal hexose carriers including GLUT-mediated uptake. Large co-ingested doses of another hexose lower the fraction of mannose absorbed intact and excreted in urine.
Mannose blocks bacterial attachment directly, while lactobacilli occupy urogenital surfaces and lower local pH. The two act on attachment from opposite sides.
Acidophilus produces lactic acid and hydrogen peroxide that discourage settlement by other organisms. That works alongside the physical blocking of fimbrial attachment by mannose.
Mannose is converted to GDP-mannose for N-linked glycan assembly, while glucosamine feeds the hexosamine pathway toward UDP-GlcNAc. Both supply the sugar donors that glycoprotein synthesis draws on.
Mannose and glucose are both taken up across the intestinal brush border by the same transporter family, with GLUT-mediated uptake shared between them. A large glucose load in the same window therefore competes with mannose for absorption capacity. That is why mannose is usually taken away from a carbohydrate-heavy meal, and it is transport chemistry rather than an interaction between two supplements.
Fructose crosses the intestinal wall largely through GLUT5 and shares onward GLUT2 handling with other hexoses. Where transport capacity overlaps, a large fructose load takes up part of it. The consequence is one of timing rather than of any chemical incompatibility.
Yeast cell walls are rich in mannan and mannoprotein, presenting mannose residues on their outer surface. Type 1 fimbrial FimH lectins on certain bacteria bind mannose residues wherever they find them, including on yeast mannan. Pairing free mannose with a mannan-bearing yeast supplies the same recognition motif from two sources; the binding chemistry is established, the clinical consequence is not established from a combination trial.
Mannose that is not absorbed in the small intestine reaches the colon, where resident bacteria can ferment it. Galactooligosaccharides are a defined fermentable substrate reaching the same compartment. Stacking two fermentable carbohydrates raises the total gas-producing load, which is the practical thing to watch rather than a benefit to assume.
Inulin ferments rapidly in the proximal colon and unabsorbed mannose arrives in the same region. The combination increases the fermentable substrate available to the microbiota at one time. People sensitive to fermentable carbohydrates feel this as bloating, so total load matters more than which sugars are in the mix.
Lactobacilli carry phosphotransferase systems capable of importing mannose and routing it into glycolysis, and several strains also present surface adhesins. Providing free mannose alongside a defined strain supplies a substrate that strain can use. Which strains actually use it varies, so the pairing should be judged strain by strain rather than at the genus level.
Ascorbate and mannose appear together in urinary support formulas, where the rationale offered is a change in urinary chemistry alongside mannose's own urinary excretion. The pairing is formulation convention with a long history rather than a tested combination. No trial has separated what each contributes.
Inositol is a cyclitol handled by its own transporters but sitting alongside the hexose pool, and mannose enters cells and is phosphorylated by hexokinase. Both feed phosphorylated sugar pools used in membrane and glycan chemistry. The connection is metabolic geography rather than a demonstrated interaction.
Dehydroascorbate, the oxidised form of vitamin C, enters cells through GLUT transporters that also carry hexoses, which is why high sugar concentrations can compete with its uptake in laboratory systems. Mannose is one of those hexoses. The competition is documented at the transporter level and its practical significance at ordinary intakes has not been established.
Nothing specific on file for Mannose. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Mannose actually does.
D-mannose is a hexose epimer of glucose, differing only at carbon two, which is why the two share transporters and why hexokinase accepts both.
Once inside a cell, mannose is phosphorylated by hexokinase to mannose-6-phosphate, converted by phosphomannomutase to mannose-1-phosphate and then to GDP-mannose, the donor sugar for N-linked glycosylation.
Mannose-6-phosphate can also be converted by mannose phosphate isomerase to fructose-6-phosphate, which routes it into glycolysis, so mannose is both a glycosylation substrate and a fuel depending on where the cell needs it.
Mannose-6-phosphate tags on lysosomal enzymes are the recognition signal that directs those enzymes to the lysosome, one of the clearest examples of a sugar residue acting as an address label in cell biology.
Where Mannose comes from.
D-mannose usually starts as a plant fibre that already contains mannose locked into long chains, often from hardwood or from seeds. That chain is broken apart, the mannose is separated out from the other sugars that come with it, and it is crystallised into a white powder. Some producers make it by fermentation or by converting fructose instead; the finished molecule is the same either way.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Commercial D-mannose is generally made from plant polysaccharides that are rich in mannose residues rather than isolated from a food directly.
The polysaccharide chain is cleaved to release free mannose along with other monosaccharides present in the source polymer.
Chromatographic separation, ion exchange and decolourisation remove glucose, galactose and other co-released sugars along with hydrolysis by-products.
The purified mannose is concentrated and crystallised out of solution, which is the step that sets its purity grade.
The crystalline material is checked for identity and purity, including confirmation that it is the D enantiomer, and residual sugars are held to a specification.
The finished sugar is milled to a target particle size and either packed as a powder or blended with flow agents for encapsulation.
Getting Mannose from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In a randomised controlled design in adult cats, D-mannose supplementation was associated with changes in immune measures and in gut microbiota composition; the findings are in cats and are compositional and marker-level.Animal study. Wang J et al., 2025 (Research in Veterinary Science). PMID 41166862 ↗
- Dietary mannose supplementation in people with an inherited enzyme deficiency affecting sugar processing did not produce a detectable change in the glycosylation measures tracked; a failure to detect a difference is not evidence that none exists.Open-label trial. Taday R et al., 2020 (Orphanet Journal of Rare Diseases). PMID 32962735 ↗
- Further reporting on mannose supplementation in the same inherited enzyme deficiency setting did not identify a benefit on the biochemical measures followed; the result is a null on those specific markers.Open-label trial. Taday R et al., 2021 (Orphanet Journal of Rare Diseases). PMID 34380532 ↗
- A single case describes management and outcomes across pregnancy in a woman with an inherited deficiency of the enzyme that converts mannose-6-phosphate, a setting where mannose is used clinically under specialist supervision; a case report describes one person and establishes nothing about a population.Case report. Loh JHM et al., 2026 (Molecular Genetics and Metabolism Reports). PMID 42376639 ↗
- D-mannose supplementation of culture medium was used as a method to expand stem-like memory T cells in vitro, which is a laboratory technique and not evidence of an effect from oral intake.In vitro study. Qiu Y et al., 2026 (Methods in Cell Biology). PMID 42177043 ↗
- Mannose exposure altered migration and invasion properties of the cultured bone cell lines examined; this is cell-culture work on isolated cell lines with no bearing on what an oral dose does in a person.In vitro study. Morita A et al., 2026 (Biology). PMID 41594862 ↗
- A computational network analysis of shared molecular links between excess body weight and reduced bone density was paired with mannose supplementation experiments; the computational part generates hypotheses rather than measuring an effect.In vitro study. James R et al., 2025 (Scientific Reports). PMID 40789846 ↗
- Osteocyte Pink1 and Prkn signalling was reported to modulate mannose-6-phosphate metabolism in the model used, which names mannose metabolism as a downstream node rather than testing mannose supplementation.Animal study. Mei J et al., 2026 (Journal of Orthopaedic Translation). PMID 42182074 ↗
These are the studies our verdict leans on, chosen from the 8 we read for Mannose. The full linked list is below.
The studies, linked.
10 sources behind our Mannose verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEffect of Hyaluronic Acid Oral Supplementation on Sexual and Urinary Symptoms of Women With Recurrent Urinary Tract InfectionsClinicalTrials.gov ↗NA · 50 participants · Completed
- Clinical trialA Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-1307-01)ClinicalTrials.gov ↗PHASE1 · 48 participants · Completed
- Clinical trialA Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian CancerClinicalTrials.gov ↗PHASE1 · 36 participants · Completed
- Clinical trialA Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of D-Mannose on Symptoms of Urinary Tract Infection in WomenClinicalTrials.gov ↗PHASE2 · 30 participants · Completed
- Clinical trialA Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)ClinicalTrials.gov ↗PHASE1 · 24 participants · Completed
- Clinical trialProject 1A) To Determine Whether the Transplacental Gradients for 6 Polyols and Mannose Are Altered in IUGR Pregnancies Compared to Normal Pregnancies. Project 1B) To Determine the Relative Contributions of Transplacental Transport vs. Production by the Conceptus of Both Myoinositol (Major Polyol) and Mannose in IUGR and Normal Pregnancies Using Stable Isotopic Methodology.ClinicalTrials.gov ↗NA · 24 participants · Terminated
- Clinical trialRandomised, Open-label, Controlled Clinical Trial to Evaluate the Efficacy of a Product Consisting of D Mannose 2 g+ Cran-max 500 mg+ Vitamin D3 0.001 mg (UROMANNOSA®) in Women With Recurrent Lower Urinary Tract InfectionsClinicalTrials.gov ↗NA · 108 participants · Suspended
- Clinical trialA Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal WomenClinicalTrials.gov ↗NA · 90 participants · Recruiting
- ClinicalTrials.gov ↗
- Clinical trialA Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and NeutropeniaClinicalTrials.gov ↗PHASE1 · Withdrawn
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 1,975 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Mannose is, not how risky it is. A report is not proof Mannose caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
